DK3077519T3 - Cmv-vacciner - Google Patents

Cmv-vacciner Download PDF

Info

Publication number
DK3077519T3
DK3077519T3 DK14820762.4T DK14820762T DK3077519T3 DK 3077519 T3 DK3077519 T3 DK 3077519T3 DK 14820762 T DK14820762 T DK 14820762T DK 3077519 T3 DK3077519 T3 DK 3077519T3
Authority
DK
Denmark
Prior art keywords
vacciner
cmv
Prior art date
Application number
DK14820762.4T
Other languages
Danish (da)
English (en)
Inventor
Farshad Guirakhoo
Karen Lingnau
Gerhard Fuhrmann
Katherine Cohen
Andreas Aspöck
Manuela Kainer
Bernhard Brim
Bettina Kiefmann
Elizabeth Watson
Mario Aistleithner
Katharina Bayer
Elsa Mühlbacher
Klaus Orlinger
Thomas Monath
Vera Baumgartl-Strasser
Original Assignee
Hookipa Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech Gmbh filed Critical Hookipa Biotech Gmbh
Application granted granted Critical
Publication of DK3077519T3 publication Critical patent/DK3077519T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14820762.4T 2013-12-03 2014-12-03 Cmv-vacciner DK3077519T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US201462055699P 2014-09-26 2014-09-26
PCT/EP2014/076466 WO2015082570A1 (en) 2013-12-03 2014-12-03 Cmv vaccines

Publications (1)

Publication Number Publication Date
DK3077519T3 true DK3077519T3 (en) 2021-06-14

Family

ID=52232138

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14820762.4T DK3077519T3 (en) 2013-12-03 2014-12-03 Cmv-vacciner

Country Status (17)

Country Link
US (3) US10111945B2 (enExample)
EP (2) EP3904522A1 (enExample)
JP (2) JP6818551B2 (enExample)
CN (2) CN115058452A (enExample)
AU (2) AU2014359276B2 (enExample)
CA (1) CA2932318C (enExample)
CY (1) CY1124288T1 (enExample)
DK (1) DK3077519T3 (enExample)
ES (1) ES2868427T3 (enExample)
HR (1) HRP20211015T1 (enExample)
HU (1) HUE054579T2 (enExample)
LT (1) LT3077519T (enExample)
PL (1) PL3077519T3 (enExample)
PT (1) PT3077519T (enExample)
RS (1) RS61993B1 (enExample)
SI (1) SI3077519T1 (enExample)
WO (1) WO2015082570A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2604695T3 (pl) 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
DK3077519T3 (en) * 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948467A (zh) * 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) * 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
US11260090B2 (en) 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
IL322403A (en) 2016-04-15 2025-09-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
CA3041307A1 (en) * 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
CA3050914A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
WO2018191666A1 (en) 2017-04-14 2018-10-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
KR102609106B1 (ko) * 2018-12-10 2023-12-05 케이엠 바이올로직스 가부시키가이샤 사이토메갈로바이러스의 선천성 감염을 예방 또는 치료하기 위한 백신
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
EP4163378A4 (en) * 2020-06-09 2024-03-13 KM Biologics Co., Ltd. Fusion protein of pentamer and gb of cytomegalovirus, and vaccine containing said fusion protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
WO2022173605A2 (en) 2021-02-10 2022-08-18 Regenxbio Inc. Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof
CN118221773B (zh) * 2024-02-05 2025-09-09 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE313560T1 (de) * 2000-03-21 2006-01-15 Genzyme Corp Therapeutische anti-cytomegalovirus verbindungen
DE102004034461B4 (de) * 2004-07-16 2008-02-07 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider Tumore durch retrovirale, mit Arenavirus-Glykoprotein pseudotypisierte Vektoren
EP1856250B1 (en) * 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill New live virus vaccines
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
WO2007109813A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
PL2604695T3 (pl) * 2007-12-27 2023-04-11 Universität Zürich Cząstka arenawirusa z defektem replikacji
US8580276B2 (en) * 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
JP2012530500A (ja) * 2009-06-26 2012-12-06 ヴェクトライト バイオメディカ インコーポレイテッド サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法
SG189176A1 (en) * 2010-10-15 2013-05-31 Glaxosmithkline Biolog Sa Cytomegalovirus gb antigen
EP2664680A1 (en) * 2011-01-07 2013-11-20 Bioscience Slovakia Antibody-based methods of diagnosing infections with lymphocytic choriomeningitis virus (LCMV)
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
GB2513768B (en) * 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
ES2751423T3 (es) 2013-03-15 2020-03-31 Univ Geneve Vacunas antimicobacterianas
DK3077519T3 (en) 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
HUE051390T2 (hu) 2014-11-13 2021-03-01 Univ Geneve Háromszegmensû arenavírusok mint vakcinavektorok
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
CN115948467A (zh) 2015-11-04 2023-04-11 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
CA3003548A1 (en) 2015-11-12 2017-05-18 Hookipa Biotech Ag Arenavirus particles as cancer vaccines
IL314272A (en) 2016-05-18 2024-09-01 Hookipa Biotech Gmbh Three-segmented PICHINDE viruses as vaccine vectors
JP2019533690A (ja) 2016-11-04 2019-11-21 ホオキパ バイオテック ジーエムビーエイチ 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子
AU2018247958A1 (en) 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
US20220380805A1 (en) 2019-11-07 2022-12-01 Universität Basel Arenaviruses as vectors
BR112022024404A2 (pt) 2020-05-29 2023-02-07 Hookipa Biotech Gmbh Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus

Also Published As

Publication number Publication date
CN105980570B (zh) 2022-06-07
HRP20211015T1 (hr) 2021-10-01
CN105980570A (zh) 2016-09-28
CY1124288T1 (el) 2022-07-22
WO2015082570A1 (en) 2015-06-11
SI3077519T1 (sl) 2021-07-30
LT3077519T (lt) 2021-04-26
HUE054579T2 (hu) 2021-09-28
JP6818551B2 (ja) 2021-01-20
US20230181725A1 (en) 2023-06-15
PT3077519T (pt) 2021-05-13
PL3077519T3 (pl) 2021-10-18
WO2015082570A8 (en) 2015-11-26
US11554169B2 (en) 2023-01-17
RS61993B1 (sr) 2021-07-30
US20160296619A1 (en) 2016-10-13
AU2014359276A1 (en) 2016-06-16
JP2017503482A (ja) 2017-02-02
JP7001807B2 (ja) 2022-02-04
EP3904522A1 (en) 2021-11-03
US20190247493A1 (en) 2019-08-15
US10111945B2 (en) 2018-10-30
CA2932318A1 (en) 2015-06-11
AU2021202541A1 (en) 2021-05-27
ES2868427T3 (es) 2021-10-21
JP2021061848A (ja) 2021-04-22
EP3077519B1 (en) 2021-03-31
HK1226440A1 (zh) 2017-09-29
CA2932318C (en) 2023-10-10
EP3077519A1 (en) 2016-10-12
AU2014359276B2 (en) 2021-01-28
CN115058452A (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T5 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
DK3470074T3 (en) Probiotika
DK3056208T3 (en) Immunpotentiator
AU353643S (en) Stamphousing
GB201301329D0 (en) Fluidfoil
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
EP3014557A4 (en) TELEPHONE ON FILE
GB201300001D0 (en) Envirep - environment replicater
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201320861D0 (en) Busuu
AU353330S (en) Kettlebell
AU353329S (en) Kettlebell
AU353331S (en) Kettlebell
AU353328S (en) Kettlebell
AU353327S (en) Kettlebell
AU353326S (en) Kettlebell
AU353325S (en) Kettlebell
AP00812S1 (en) Stumbelbloc